Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
Zactima will be used in this study to determine the highest dose that can be given safely as
well as the side effects of Zactima when in combination with two FDA approved drugs;
gemcitabine and capecitabine. This combination will be given to patients with advanced solid
tumors. Once the highest dose of the combination has been determined, additional patients
with biliary cancers (cholangiocarcinomas and gallbladder cancer) and locally advanced or
metastatic pancreatic cancer will be treated at the highest determined dose for further
studies.